相关实验视频

Updated: May 6, 2026

Tracking the Mammary Architectural Features and Detecting Breast Cancer with Magnetic Resonance Diffusion Tensor Imaging

Tracking the Mammary Architectural Features and Detecting Breast Cancer with Magnetic Resonance Diffusion Tensor Imaging

Published on: December 15, 2014

DCTPP1表达作为化学疗法响应的预测器在光线A乳腺癌患者的乳腺癌患者

Juan P Muñoz¹, Diego Soto-Jiménez¹, Gloria M Calaf²

¹Laboratorio de Bioquímica, Departamento de Química, Facultad de Ciencias, Universidad de Tarapacá, Arica 1000007, Chile.

|August 29, 2024

概括

乳腺癌 (BRCA) 中脱氧化三酸盐酸酶1 (DCTPP1) 的高表达与生存率低下和化疗耐药性有关. DCTPP1可以作为治疗反应的生物标志物和改善BRCA治疗的目标.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
基因组学就是基因组学.

背景情况:

乳腺癌 (BRCA) 构成了重大的健康挑战,治疗结果往往受到化学抵抗的限制.
了解化学抵抗的分子基础对于开发有效的治疗策略至关重要.
人类脱氧化三酸盐酸酶1 (DCTPP1) 涉及核酸代谢和基因组稳定性,在癌症进展和耐药性方面具有潜在的作用.

研究的目的:

研究DCTPP1在乳腺癌 (BRCA) 预后和化疗反应中的作用.
评估DCTPP1作为BRCA患者化疗疗效能的潜在预测生物标志物.

主要方法:

使用TCGA,GTEx和GEO存储库的数据分析DCTPP1表达.
使用GEPIA和Kaplan-Meier Plotter进行生存和表达分析.
在使用化疗剂治疗的BRCA细胞系上进行了体外研究.

主要成果:

增加DCTPP1表达与BRCA患者的整体存活率较差相关.
高DCTPP1水平与化学疗法耐药性增加有关,特别是在ER阳性,光线A亚型患者中.
在非响应者和在光线A BRCA细胞系中使用5-甲和多克索鲁比辛治疗后,DCTPP1基因表达增加.

结论:

DCTPP1是预测乳腺癌 (BRCA) 化疗反应的潜在生物标志物.
向DCTPP1可能提供一种克服抗化学性和提高BRCA治疗疗效的策略.

关键词:

DCTPP1 DCTPP1 是一个乳腺癌乳腺癌乳腺癌化学电阻是一种化学电阻.发光线A A 的光线.预后预后预后

更多相关视频

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...